LVT has a rigorous R&D program. With global reach, LVT's R&D plan benefits from the vast intellectual resources and partnerships with foreign companies. LVT actively uses these foreign resources for its testing and development, product sourcing and technology planning. Locally in the U.S., chemists, formulation professionals, manufacturing technicians and regulatory specialists also contribute to these efforts. LVT's R&D program consists of the following items:
Development of generic drug product formulations for inclusion in ANDA submissions to the FDA. LVT currently has 10 ANDAs at various stages of development, including pending FDA approval. Of these, three are oral solution products; and seven are solid dosage products.
Development of unique product formulations for inclusion in NDA submissions to the FDA. LVT currently has 4 NDAs at various stages of development, including products with multiple dosage forms and routes of administration.
Acquisition of NDAs and ANDAs for market participations
Development of Diversion and Abuse Resistant Technologies (DART) to be utilized by dosage manufacturers to improve a product's resistance to the illegal diversion of the drug product for illicit purposes. See DART for more information about this technology.
